Trial register facet
Trial records in chronic kidney disease in type 2 diabetes
15 records bearing on chronic kidney disease in type 2 diabetes.
Showing 0 records on this page
Records
15 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| FLOW | Semaglutide | Phase 3 | Reported | Event-driven kidney outcome trial | 3,533 | 2024 | High |
| FLOW-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| AMPLITUDE-O | Exenatide | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 4,076 | 2021 | Moderate |
| AMPLITUDE-O-REGIONAL-JPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AMPLITUDE-O-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2021 | Very low |
| AWARD-7 | Dulaglutide | Phase 3 | Reported | Randomised, open-label, active-controlled | 576 | 2018 | Low |
| AWARD-7-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-BODY-COMPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| AWARD-7-RENAL-IMPprogramme record | Dulaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2018 | Very low |